Compare PFG & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PFG | ILMN |
|---|---|---|
| Founded | 1879 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.6B | 18.9B |
| IPO Year | N/A | 2000 |
| Metric | PFG | ILMN |
|---|---|---|
| Price | $87.67 | $128.82 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 10 | 15 |
| Target Price | $88.40 | ★ $114.93 |
| AVG Volume (30 Days) | 1.3M | ★ 1.5M |
| Earning Date | 10-27-2025 | 10-30-2025 |
| Dividend Yield | ★ 3.61% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 6.91 | 4.46 |
| Revenue | ★ $15,800,800,000.00 | $4,288,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.78 | $2.08 |
| P/E Ratio | ★ $12.66 | $28.91 |
| Revenue Growth | ★ 12.33 | N/A |
| 52 Week Low | $68.39 | $68.70 |
| 52 Week High | $90.31 | $153.06 |
| Indicator | PFG | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 67.39 | 66.70 |
| Support Level | $83.50 | $124.27 |
| Resistance Level | $85.51 | $129.72 |
| Average True Range (ATR) | 1.86 | 3.90 |
| MACD | 0.25 | -0.41 |
| Stochastic Oscillator | 96.65 | 77.82 |
Principal Financial Group Inc is a financial services provider. It offers various financial products and services including retirement, asset management, and workplace benefits and protection solutions to individuals and institutional clients. The company, along with its subsidiaries, operates in the following reportable segments; Retirement and Income Solutions, Principal Asset Management, and Benefits and Protection. Maximum revenue is generated from the Retirement and Income Solutions segment which provides workplace savings and retirement solutions, banking, trust and custodial services, individual variable annuities (including RILAs), pension risk transfer, and investment services to businesses, their employees, and other individuals.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.